Product Description:

• KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for:
• the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
• received prior therapy for metastatic disease, or
• developed disease recurrence during or within six months of completing adjuvant therapy.

How to use:

• Administered as an infusion by a clinical expert who has been certified. Your primary care physician will determine which portion of the supplement is essential and how frequently you should take it.
• This will vary depending on the condition for which you are being treated and may change from time to time.

Caution & Warnings:

• Pulmonary Toxicity
• Hypersensitivity Reactions
• Hemorrhage
• Thrombocytopenia
• Neurotoxicity

Side Effects:

• Fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.

Ingredients:

• Ado-trastuzumab emtansine (160mg)